Product Details
| Product Name:
TA-01 |
CAS No.:
1784751-18-3 |
| Purity:
99.94% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | TA-01 |
| Description | TA-01 is a potent inhibitor of CK1 and p38 MAPK, with IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK. |
| Cell Research | HES-3, H7 and IPS are harvested and seeded at 1.1 × 106 cells/mL as EBs in ultra-low attachment 12-well plates in bSFS medium: DMEM supplemented with 2 mM l-glutamine, 0.182 mM sodium pyruvate, 1% non-essential amino acids, 0.1 mM β-mercaptoethanol, 5.6 mg/L transferrin, 20 μg/L sodium selenite, 0.25% (w/vol) Bovine Serum Albumin and 0.25% (w/vol) Hysoy. Cells are incubated at 37°C and 5% CO2 to allow EB formation. The medium is refreshed after 1 day and then every 2-3 days. Cells are stimulated with the respective compounds (TA-01) dissolved in DMSO (1 μL DMSO/mL of media) starting from day 1 or day 4, until day 8. CHIR99021 is applied for the first 24 h only[1]. |
| Kinase Assay | Compounds (TA-01) are dissolved in DMSO?and tested at?10 μM concentrations?against a panel of 97 kinases, which are related to stem cell differentiation and cell signaling pathways. Kinome profiling is carried out by kinase profiling service[1]. |
| In vitro | TA-01, a potent inhibitor of CK1 and p38 MAPK, demonstrates IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK. At a concentration of 5 μM, TA-01 is non-cytotoxic and completely inhibits cardiogenesis, although it induces cardiogenesis at lower concentrations[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 9 mg/mL (25.62 mM)
|
| Keywords | TA01 | Inhibitor | Casein Kinase | Autophagy | p38 MAPK | inhibit | TA 01 | TA-01 |
| Inhibitors Related | Stavudine | Xylitol | Myricetin | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Neural Regeneration Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:215778-97-5
$39.00 / 1mg
-
CAS:1784751-19-4
$33.00 / 5mg
-
CAS:5778-80-3
$80.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/25kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-03-09 |
|
|
$2500.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
|
|
$2780.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States